Savvy Advisors Inc. Acquires 2,635 Shares of Boston Scientific Corporation $BSX

Savvy Advisors Inc. grew its stake in Boston Scientific Corporation (NYSE:BSX) by 30.1% in the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 11,392 shares of the medical equipment provider’s stock after buying an additional 2,635 shares during the quarter. Savvy Advisors Inc.’s holdings in Boston Scientific were worth $1,224,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently modified their holdings of the company. HM Payson & Co. lifted its position in shares of Boston Scientific by 1.4% in the first quarter. HM Payson & Co. now owns 6,875 shares of the medical equipment provider’s stock valued at $694,000 after acquiring an additional 98 shares in the last quarter. Riverwater Partners LLC grew its holdings in shares of Boston Scientific by 3.3% in the second quarter. Riverwater Partners LLC now owns 3,104 shares of the medical equipment provider’s stock valued at $333,000 after purchasing an additional 98 shares in the last quarter. IVC Wealth Advisors LLC increased its holdings in shares of Boston Scientific by 4.9% in the 2nd quarter. IVC Wealth Advisors LLC now owns 2,199 shares of the medical equipment provider’s stock worth $236,000 after buying an additional 102 shares during the last quarter. Park Square Financial Group LLC increased its stake in Boston Scientific by 5.2% during the first quarter. Park Square Financial Group LLC now owns 2,066 shares of the medical equipment provider’s stock worth $208,000 after acquiring an additional 103 shares during the last quarter. Finally, HHM Wealth Advisors LLC increased its position in shares of Boston Scientific by 13.2% during the 1st quarter. HHM Wealth Advisors LLC now owns 881 shares of the medical equipment provider’s stock valued at $89,000 after purchasing an additional 103 shares during the last quarter. 89.07% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

BSX has been the topic of a number of recent analyst reports. Barclays increased their price objective on shares of Boston Scientific from $133.00 to $136.00 and gave the stock an “overweight” rating in a research report on Thursday, October 2nd. Leerink Partners upped their price objective on shares of Boston Scientific from $127.00 to $128.00 and gave the stock an “outperform” rating in a research note on Wednesday, October 1st. The Goldman Sachs Group reiterated a “buy” rating and issued a $124.00 price target on shares of Boston Scientific in a report on Wednesday, October 22nd. Weiss Ratings reiterated a “buy (b-)” rating on shares of Boston Scientific in a research note on Wednesday, October 8th. Finally, UBS Group upped their target price on Boston Scientific from $135.00 to $140.00 and gave the company a “buy” rating in a research report on Thursday, October 23rd. Two equities research analysts have rated the stock with a Strong Buy rating, twenty-one have given a Buy rating and two have given a Hold rating to the stock. According to MarketBeat, Boston Scientific currently has an average rating of “Buy” and an average target price of $123.77.

Boston Scientific Trading Up 0.2%

Boston Scientific stock opened at $100.55 on Friday. The firm has a market cap of $148.98 billion, a PE ratio of 53.77, a P/E/G ratio of 2.02 and a beta of 0.61. The company has a current ratio of 1.37, a quick ratio of 0.82 and a debt-to-equity ratio of 0.49. The stock’s 50 day simple moving average is $100.87 and its two-hundred day simple moving average is $102.25. Boston Scientific Corporation has a 12 month low of $83.38 and a 12 month high of $109.50.

Boston Scientific (NYSE:BSX) last issued its quarterly earnings data on Wednesday, October 22nd. The medical equipment provider reported $0.75 earnings per share for the quarter, topping analysts’ consensus estimates of $0.71 by $0.04. The business had revenue of $5.07 billion during the quarter, compared to the consensus estimate of $4.97 billion. Boston Scientific had a net margin of 14.43% and a return on equity of 19.74%. The company’s revenue was up 20.3% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $0.63 earnings per share. Boston Scientific has set its FY 2025 guidance at 3.020-3.040 EPS. Q4 2025 guidance at 0.770-0.790 EPS. Analysts anticipate that Boston Scientific Corporation will post 2.85 earnings per share for the current year.

Insider Activity

In other Boston Scientific news, Director Ellen M. Zane sold 2,901 shares of the stock in a transaction dated Tuesday, October 28th. The shares were sold at an average price of $102.24, for a total value of $296,598.24. Following the completion of the sale, the director owned 24,134 shares in the company, valued at approximately $2,467,460.16. This represents a 10.73% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Joseph Michael Fitzgerald sold 50,000 shares of Boston Scientific stock in a transaction on Wednesday, October 1st. The stock was sold at an average price of $98.47, for a total value of $4,923,500.00. Following the transaction, the executive vice president owned 178,342 shares in the company, valued at approximately $17,561,336.74. This represents a 21.90% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last quarter, insiders sold 112,891 shares of company stock worth $11,501,887. 0.50% of the stock is currently owned by insiders.

Boston Scientific Company Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.